https://www.cnbc.com/2024/02/08/ew-scripps-ceo-wall-street-misunderstands-new-sports-joint-venture.html
Feb 08, 2024 - Investors are miscalculating the bundle's popularity and incorrectly pricing in that local stations won't be included, EW Scripps CEO Adam Symson told CNBC.
0
cnbc:2290269572991021976
0
https://www.zacks.com/stock/news/2222138/compared-to-estimates-edwards-lifesciences-ew-q4-earnings-a-look-at-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm-2222138
Feb 06, 2024 - Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zc:-5432590008675396931
0
https://www.zacks.com/stock/news/2232608/holx-or-ew-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2232608
Feb 27, 2024 - HOLX vs. EW: Which Stock Is the Better Value Option?
zc:7116373311381668629
0
https://www.zacks.com/stock/news/2240686/buy-5-medical-devices-stocks-for-a-stable-portfolio-in-2024?cid=CS-ZC-FT-analyst_blog|investment_ideas-2240686
Mar 14, 2024 - We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.
zc:5542515259158012972
0
https://www.zacks.com/stock/news/2247654/here-s-why-investors-should-hold-teladoc-tdoc-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2247654
Mar 28, 2024 - Teladoc's (TDOC) Integrated Care business is expected to gain from margin expansion and improving chronic care program enrollment.
zc:-7539268432179903511
0
https://www.zacks.com/stock/news/2253585/will-unitedhealth-s-unh-unitedhealthcare-unit-aid-q1-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2253585
Apr 10, 2024 - UnitedHealth's (UNH) first-quarter results are expected to benefit from an increase in UnitedHealthcare's Community & State revenues and the number of people it served.
zc:-2163871940917110272
0
https://www.zacks.com/stock/news/2254571/what-s-in-store-for-abbott-laboratories-abt-in-q1-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2254571
Apr 12, 2024 - Abbott (ABT) is likely to have progressed with its initiative to commercialize several biosimilars in emerging markets.
zc:-5876254083692607607
0
https://www.zacks.com/commentary/2255364/3-medical-instruments-stocks-to-buy-amid-improving-industry-trends?cid=CS-ZC-FT-industry_outlook-2255364
Apr 15, 2024 - The Zacks Medical - Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt growth. EW, DXCM and STE appear well-poised to brave the challenges.
zc:-2583494088093073806
0
https://www.zacks.com/stock/news/2255600/what-s-in-store-for-thermo-fisher-tmo-in-q1-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2255600
Apr 15, 2024 - Strength in Analytical Instrument and Laboratory Products and Services segments are likely to have driven Thermo Fisher's (TMO) first-quarter 2024 performance.
zc:3981072332015869995
0
https://www.zacks.com/stock/news/2256177/what-s-in-store-for-boston-scientific-bsx-in-q1-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2256177
Apr 16, 2024 - Boston Scientific (BSX) is expected to have registered strong growth in the Asia Pacific, led by strength in China, Japan and Latin America.
zc:-6457106060917456620
0